Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SPRYCEL | Bristol Myers Squibb | N-021986 RX | 2006-06-28 | 6 products, RLD |
PHYRAGO | Handa Pharma | N-216099 RX | 2023-12-05 | 6 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
dasatinib | ANDA | 2025-03-04 |
dasatinib dasatinib | ANDA | 2025-02-25 |
phyrago | New Drug Application | 2024-12-13 |
sprycel | New Drug Application | 2024-07-31 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
myeloid leukemia | — | D007951 | C92 |
lymphoid leukemia | — | D007945 | C91 |
Expiration | Code | ||
---|---|---|---|
DASATINIB, SPRYCEL, BRISTOL MYERS SQUIBB | |||
2026-06-21 | PED | ||
2025-12-21 | ODE-225 | ||
2025-05-09 | PED | ||
2024-11-09 | ODE-164 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 17 | 28 | 6 | 1 | 9 | 53 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 11 | 18 | 6 | 1 | 10 | 41 |
Myeloid leukemia | D007951 | — | C92 | 11 | 18 | 5 | 1 | 7 | 38 |
Myeloid leukemia chronic-phase | D015466 | — | — | 3 | 4 | 2 | 1 | 3 | 13 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoid leukemia | D007945 | — | C91 | 5 | 10 | 1 | — | — | 12 |
Philadelphia chromosome | D010677 | — | — | 4 | 7 | 2 | — | — | 10 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 3 | 5 | 2 | — | — | 8 |
Prostatic neoplasms | D011471 | — | C61 | 1 | 6 | 1 | — | — | 7 |
Myeloid leukemia accelerated phase | D015465 | — | — | — | 1 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 6 | 13 | — | — | — | 14 |
Neoplasms | D009369 | — | C80 | 8 | 3 | — | — | — | 11 |
Non-small-cell lung carcinoma | D002289 | — | — | 4 | 7 | — | — | — | 9 |
Lung neoplasms | D008175 | — | C34.90 | 3 | 5 | — | — | — | 6 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 3 | 5 | — | — | — | 6 |
Lymphoma | D008223 | — | C85.9 | 1 | 4 | — | — | 1 | 5 |
Glioblastoma | D005909 | EFO_0000515 | — | 5 | 2 | — | — | — | 5 |
Blast crisis | D001752 | — | — | 2 | 3 | — | — | — | 4 |
Multiple myeloma | D009101 | — | C90.0 | 2 | 1 | — | — | — | 3 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 3 | — | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Plasma cell neoplasms | D054219 | — | — | 2 | — | — | — | — | 2 |
Colorectal neoplasms | D015179 | — | — | 2 | — | — | — | — | 2 |
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Gliosarcoma | D018316 | — | — | 2 | — | — | — | — | 2 |
Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | — | 1 |
Waldenstrom macroglobulinemia | D008258 | — | C88.0 | 1 | — | — | — | — | 1 |
Central nervous system diseases | D002493 | — | G96.9 | 1 | — | — | — | — | 1 |
Brain diseases | D001927 | — | G93.40 | 1 | — | — | — | — | 1 |
Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
Astrocytoma | D001254 | EFO_0000271 | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pleural effusion | D010996 | — | J90 | — | — | — | — | 1 | 1 |
Urinary bladder neoplasms | D001749 | — | C67 | — | — | — | — | 1 | 1 |
Transitional cell carcinoma | D002295 | — | — | — | — | — | — | 1 | 1 |
Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 1 | 1 |
Drug common name | Dasatinib |
INN | dasatinib |
Description | Dasatinib (anhydrous) is an aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN). It has a role as a tyrosine kinase inhibitor, an anticoronaviral agent and an antineoplastic agent. It is a secondary amino compound, a tertiary amino compound, an organochlorine compound, an aminopyrimidine, a member of 1,3-thiazoles, a monocarboxylic acid amide, a N-arylpiperazine and a N-(2-hydroxyethyl)piperazine. It is a conjugate base of a dasatinib(1+). |
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1 |
PDB | — |
CAS-ID | 302962-49-8 |
RxCUI | 1546019 |
ChEMBL ID | CHEMBL1421 |
ChEBI ID | 49375 |
PubChem CID | 3062316 |
DrugBank | DB01254 |
UNII ID | X78UG0A0RN (ChemIDplus, GSRS) |